Differential (Click to cross reference) advances in neurology adverse drug reaction alemtuzumab children complications cop 1 disability, neurological disease modifying agents efficacy fingolimod fumarate gadolinium immunosuppressive agents laquinimod monoclonal antibodies MRI MRI, abnormal MRI, contrast enhanced multiple sclerosis multiple sclerosis, children multiple sclerosis, relapsing multiple sclerosis, treatment of natalizumab neuroprotective agents nonsteroidal anti-inflammatory drug ocrelizumab placebo review article risk-benefit assessment safety teriflunomide treatment of neurologic disorder

Showing articles 0 to 7 of 7 Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis Neurol 102:e208006, Ng, HS.,et al, 2024 Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018 Newer Agents in the Treatment of Multiple Sclerosis Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015 Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis NEJM 367:1098-1106,1149, Gold, R.,et al, 2012 Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012 Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study Lancet 372:1463-1472, Kappos,L.,et al, 2008 Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial Lancet 390:2481-2489, Green, A.J.,et al, 2017 Showing articles 0 to 7 of 7